Synchrogenix Appoints Two New Global Submissions Directors

Synchrogenix Appoints Two New Global Submissions Directors

WILMINGTON, Del., Oct. 23, 2014 /PRNewswire/ -- Synchrogenix Information Strategies Inc., a regulatory writing company headquartered in Wilmington, Delaware, is pleased to announce the addition of two new Global Submissions Directors; Kelley Hill; Cambridge, Massachusetts; and Aaron Bernstein; Bloomfield, New Jersey.

Synchrogenix, A Certara Company, provides global regulatory writing services to the pharmaceutical, biotechnology, and medical device industry worldwide.
Kelley Hill brings over 16 years of pharmaceutical experience in drug development to Synchrogenix. Ms. Hill's experience extends from target identification through regulatory submissions and post-marketing activities with particular expertise in rare diseases, orphan drugs, and oncology. Most recently, she has been responsible for managing the medical and regulatory writing activities for multiple projects across 10 development programs. Additionally, Ms. Hill has accrued 16 years in academic experience across the life sciences.

Dr. Aaron Bernstein is a regulatory writing and business analyst expert with over 20 years of experience. Dr. Bernstein has been instrumental in developing and leading writing teams for the submission of clinical and regulatory documents to Health Authorities worldwide. His therapeutic expertise includes metabolic diseases, HIV/AIDS, and cardiology. He will be joining Synchrogenix to pioneer the new office location in Bloomfield, New Jersey.

"Kelley and Aaron are highly respected leaders and recognized mentors in our industry," said Ellen Barrosse, CEO and founder of Synchrogenix. "I am very excited to add their expertise to the exceptional team we've built."

About Synchrogenix, a Certara Company

Synchrogenix, a Certara company, encompasses a group of separate entities operating together to provide regulatory writing services to the pharmaceutical, biotech, and medical device industry worldwide. Synchrogenix Information Strategies Inc.; SynchroWest, Inc.; Synchrogenix Europe, Ltd.; and Synchrogenix Philippines, Inc., (SPI) are all wholly owned subsidiaries with an overall governance structure that creates and enforces a global standard of service, technology, and quality.

Logo - http://photos.prnewswire.com/prnh/20141023/153957LOGO


SOURCE Synchrogenix Information Strategies Inc.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.